Articles in Featured
Lately, the generics industry has been bashed from all sides with regards to quality, with most of the criticism being directed towards poor Quality-Control standards in Chinese manufacturing facilities. But this month was a terrible …
“If you can’t beat them, join them”. So goes the old saying that is proving more true day-by-day in the pharma industry. A few years ago it would have been unthinkable that Pfizer, the world’s …
Even as patents on huge blockbuster drugs are still expiring, the smart generics companies have been preparing for some time for a future in which there are fewer and fewer syntehsized molecules to copy and …
The first generics casualty of the financial crisis was Ratiopharm which is now being sold my the Merckle family to make up for their recent stock market losses. Now Actavis, the fifth largest generics company …
You know the big-pharma club is in trouble when most of its members are jumping ship from fighting against generics to producing generics themselves. Novartis, GSK, Sanofi and Daiichi are just a few examples of …
On 15 January 2008 the European Commission launched an inquiry into competition in the pharmaceuticals sector led by Competition Commissioner Neelie Kroes.
The report finds that big pharma uses a number of strategies to block …
In a sign that even the top Indian manufacturers are still struggling to meet cGMP standards, Ranbaxy has recently gotten into hot water over manufacturing violations that led to the US FDA blocking imports from …
So just as we’re writing about research pharma buying into generics companies to increase their presence in emerging markets, we see on the F.A.Z. Insitute’s Chemical Newsflash that Sanofi-Aventis, worlds 6th largest pharma company, has …
